UCB acquires the Patient Insights Business of IMIDomics, gaining access to a large IMID dataset and biobank to advance precision-driven drug discovery.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
UCB has acquired the Patient Insights Business of IMIDomics, gaining access to a large, deeply curated dataset in immune-mediated inflammatory diseases (IMIDs). The companies said the deal will strengthen UCB’s precision medicine capabilities and support faster therapeutic discovery and development.
The acquired business is built on more than 18 years of clinical and molecular data. It combines epidemiological data, detailed clinical histories, imaging, multi-omics profiles, and longitudinal patient samples. These data are collected through a network of more than 300 investigators across over 130 recruiting centers.
A key component of the platform is the IMID Biobank at the Vall d’Hebron Institute of Research in Barcelona. The biobank includes samples from more than 17,000 patients and is considered one of the most comprehensive collections focused on IMIDs.
According to Alistair Henry, Executive Vice President & Chief Scientific Officer at UCB, the acquisition aligns with UCB’s strategy to build a strong human data–driven platform in immune-mediated diseases. He noted that IMIDomics has developed a dataset and research network over a decade that would be difficult to replicate, and that integrating these resources will improve UCB’s ability to develop treatments based on patient biology.
Sara Marsal Founder and Chief Medical Officer of IMIDomics Inc. stated that the platform was designed to incorporate patient biology and clinical data into drug development. She added that UCB’s capabilities and infrastructure are expected to help expand the platform’s impact in identifying new therapeutic targets and improving outcomes for patients with IMIDs.
Under the agreement, UCB will gain access to IMIDomics’ research personnel, laboratory infrastructure, proprietary genetics and multi-omics datasets, and analytical platform. The deal also includes continued access to biological samples and associated data managed through VHIR under existing contractual frameworks.
The platform uses advanced biostatistics, machine learning, and artificial intelligence to identify disease subtypes, biomarkers, and potential therapeutic targets. These tools are intended to reduce development risk and improve the efficiency of clinical research.
Financial terms of the acquisition were not disclosed.
Reference
About the Writer
Samiksha Vikram Jadhav is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.